A Comprehensive Evaluation of Sdox, a Promising H(2)S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors

Sdox is a hydrogen sulfide (H(2)S)-releasing doxorubicin effective in P-glycoprotein-overexpressing/doxorubicin-resistant tumor models and not cytotoxic, as the parental drug, in H9c2 cardiomyocytes. The aim of this study was the assessment of Sdox drug-like features and its absorption, distribution...

Descripción completa

Detalles Bibliográficos
Autores principales: Alov, Petko, Al Sharif, Merilin, Aluani, Denitsa, Chegaev, Konstantin, Dinic, Jelena, Divac Rankov, Aleksandra, Fernandes, Miguel X., Fusi, Fabio, García-Sosa, Alfonso T., Juvonen, Risto, Kondeva-Burdina, Magdalena, Padrón, José M., Pajeva, Ilza, Pencheva, Tania, Puerta, Adrián, Raunio, Hannu, Riganti, Chiara, Tsakovska, Ivanka, Tzankova, Virginia, Yordanov, Yordan, Saponara, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936434/
https://www.ncbi.nlm.nih.gov/pubmed/35321325
http://dx.doi.org/10.3389/fphar.2022.831791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936434/
https://www.ncbi.nlm.nih.gov/pubmed/35321325
http://dx.doi.org/10.3389/fphar.2022.831791

Ejemplares similares